Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: Controversial points and a promising arena
Journal of Diabetes · 2023
DOI: 10.1111/1753-0407.13389 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Diabetes, 2023. Verfasst von Faisal Holil AlAnazi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, College of Medicine, Majmaah University, Majmaah, Saudi Arabia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Resistance, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neprilysin (NEP) is a transmembrane zinc‐dependent metalloproteinase that inactivates various peptide hormones including glucagon‐like peptide 1 (GLP‐1). NEP inhibitors may be effective in the management of type 2 diabetes mellitus (T2DM) by increasing the circulating level of GLP‐1. However, acute‐effect NEP inhibitors may lead to detrimental effects by increasing blood glucose independent of GLP‐1. These findings suggest a controversial point regarding the potential role of NEP inhibitors on glucose homeostasis in T2DM patients. Therefore, this perspective aimed to clarify the controversial points concerning the role of NEP inhibitors on glucose homeostasis in T2DM. NEP inhibitors may lead to beneficial effects by inhibition of NEP, which is involved in the impairment of glucose homeostasis through modulation of insulin resistance. NEP increases dipeptidyl peptidase‐4 (DPP4) activity and contributes to increasing active GLP‐1 proteolysis so NEP inhibitors may improve glycemic control through increasing endogenous GLP‐1 activity and reduction of DPP4 activity. Thus, NEP inhibitors could be effective alone or in combination with antidiabetic agents in treating T2DM patients. However, long‐term and short‐term effects of NEP inhibitors may lead to a detrimental effect on insulin sensitivity and glucose homeostasis through different mechanisms including augmentation of substrates and pancreatic amyloid deposition. These findings are confirmed in animal but not in humans. In conclusion, NEP inhibitors produce beneficial rather than detrimental effects on glucose homeostasis and insulin sensitivity in humans though most of the detrimental effects of NEP inhibitors are confirmed in animal studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, College of Medicine, Majmaah University, Majmaah, Saudi Arabia.
- Department of Clinical Pharmacology and Medicine, College of Medicine, ALmustansiriyia University, Baghdad, Iraq.
- Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, New South Wales, Australia.
- AFNP Med, Wien, Austria.
- Department of Surgery II, University Hospital Witten-Herdecke, University of Witten-Herdecke, Wuppertal, Germany.
- Chemistry Department, College of Science, King Khalid University, Abha, Saudi Arabia.
ORCID-Profile: Hanan A Ogaly, Yousef Abud Alanazi, Hebatallah M Saad
Zitieren
APA
AlAnazi, F. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A., Papadakis, M., Ogaly, H. A., Alanazi, Y. A., Saad, H. M., & Batiha, G. E. (2023). Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: Controversial points and a promising arena. Journal of Diabetes. https://doi.org/10.1111/1753-0407.13389
Vancouver
AlAnazi FH, Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Ogaly HA, et al. Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: Controversial points and a promising arena. Journal of Diabetes. 2023. doi:10.1111/1753-0407.13389
BibTeX
@article{AlAnazi2023,
author = {AlAnazi, Faisal Holil and Al-Kuraishy, Hayder M and Al-Gareeb, Ali I and Alexiou, Athanasios and Papadakis, Marios and Ogaly, Hanan A and Alanazi, Yousef Abud and Saad, Hebatallah M and Batiha, Gaber El-Saber},
title = {Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: Controversial points and a promising arena},
journal = {Journal of Diabetes},
year = {2023},
doi = {10.1111/1753-0407.13389}
}
EUVIMED